Coronavirus (COVID-19)

COVID-19 Monoclonal Antibody Infusion Centers for Adult Patients

The US FDA granted emergency use authorization (EUA) for select monoclonal antibody therapies for use as both treatment and post-exposure prophylaxis (prevention) of COVID-19. Studies have shown that these therapies may reduce the risk of developing symptomatic COVID-19, hospitalization, and/or mortality due to COVID-19 in high-risk patients. The State of Rhode Island has received a limited supply of these medications for use, and the available inventory has been divided among hospital systems across the state.

These monoclonal antibodies will be administered as an intravenous infusion delivered in the outpatient setting for those high-risk individuals who have either had an exposure to COVID-19 or tested positive for COVID-19. Patients should be referred by their primary care provider or urgent care provider to the Infectious Diseases (ID) Center using the referral form below. Referred patients will be evaluated by the ID clinical team for eligibility, and order will be placed by ID provider, if eligible. 

If you meet the criteria below and are interested in this treatment, please speak with your primary care or urgent care provider about a referral. 

Information for Referring Providers

Hours of Service

Referral hours of operation are Monday through Friday, 8 a.m. to 4:30 p.m.

Eligibility Criteria

Patients must meet the criteria as defined in the EUA as described below. More information about the EUA (

Referrals for Treatment of COVID-19

  1. Patient has a positive test result for SARS-CoV-2
  2. Patient is presenting within 10 days of symptom onset and hospitalization due to COVID-19 is not anticipated
  3. Patient is not requiring supplemental oxygen due to COVID-19
  4. Patient is at high risk for progressing to severe COVID-19. For information on medical conditions and factors associated with increased risk for progression to severe COVID, see the CDC website.

Information to Review with Eligible Patients

If a patient is eligible and you would like to refer them, please review the EUA fact sheet below with the patient and ensure the patient agrees to treatment. Final determination of which monoclonal antibody the patient receives will be determined by available inventory or will be at the discretion of the ID clinical team.

How to Refer a Patient

Please review the referring provider criteria (above), then fill out the referral form and fax it to Lifespan at 401-793-7659.